首页膀胱肿瘤治疗及预后证据详情

Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer

原文: 2021 年 发布于 Lasers in Medical Science 11 卷 第 06 期 506-520 浏览量:210次

作者: Pessoa R. R. Mueller A. C. Boxley P. Flaig T. W. Piper C. Konety B. Yu J. M. B. Gershman B. Kukreja J. Kim S. P.

作者单位: Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy. Department of Woman, Child and General and Specialized Surgery, Urology Unit, University of Campania 'Luigi Vanvitelli', 80131 Naples, Italy.

归属分类: 膀胱肿瘤治疗及预后证据

DOI: 10.1016/j.purol.2020.09.020

关键词: 非浸润性膀胱癌 钬激光肿瘤切除术 传统电切 荟萃分析

文献简介

BACKGROUND: Photodynamic diagnosis and narrow-band imaging could help improve the detection rate in transurethral resection (TUR) of bladder cancer. It remained controversial that the novel visualization method assisted transurethral resection (VA-TUR) could elongate patients' survival compared to traditional TUR. METHODS: We performed electronic and manual searching until December 2020 to identify randomized controlled trials comparing VA-TUR with traditional TUR, which reported patients' survival data. Two reviewers independently selected eligible studies, extracted data, assessed the risk of bias. Meta-analysis was conducted according to subgroups of types of visualization methods (A) and clinical stage of participants. Publication bias was detected. RESULTS: We included 20 studies (reported in 28 articles) in this review. A total of 6,062 participants were randomized, and 5,217 participants were included in the analysis. Only two studies were assessed at low risk of bias. VA-TURB could significantly improve the recurrence-free survival (RFS) (HR = 0.72, 95% CI: 0.66 to 0.79, P <0.00001, I(2) = 42%) and progression-free survival (PFS) (HR = 0.62, 95% CI: 0.46 to 0.82, P <0.0008, I(2) = 0%) compared with TUR under white light. The results remain stable whatever the type of visualization method. The difference could be observed in the non-muscle-invasive bladder cancer (NMIBC) population (P <0.05) but not in the mixed population with muscle-invasive bladder cancer (MIBC) participants (P >0.05). CONCLUSION: VA-TUR could improve RFS and PFS in NMIBC patients. No significant difference is found among different types of VA-TUR. VA-TUR may be not indicated to MIBC patients.

热门文献